TIMP3 Expression Associates with Prognosis in Colorectal Cancer and Its Novel Arylsulfonamide Inducer, MPT0B390, Inhibits Tumor Growth, Metastasis and Angiogenesis

Overview

Journal Theranostics

Date 2019 Oct 8

PMID 31588243

Citations 17

Authors

Han-Li Huang

Yi-Min Liu

Ting-Yi Sung

Tsui-Chin Huang

Ya-Wen Cheng

Jing-Ping Liou

Shiow-Lin Pan

Affiliations

Soon will be listed here.

Abstract

Tissue inhibitors of metalloproteinase 3 (TIMP3) are a major endogenous inhibitor of matrix metalloproteinase (MMPs) that inhibit tumor growth, invasion, metastasis and angiogenesis. In this study, we found that TIMP3 expression is associated with positive prognosis of colorectal cancer (CRC) clinicopathologically. Therefore, we developed a series of arylsulfonamide derivatives as inducers in order to define potential colorectal cancer therapeutic agent. Among these, MPT0B390 was selected for anti-tumor, anti-metastasis, and anti-angiogenesis property determination. The relationship between TIMP3 expression and clinical pathological features in colorectal patients and cell lines were determined by immunohistochemistry, bioinformatics analysis and western blotting. The anti-tumor function was validated by using MTT, apoptosis pathway detection and xenograft model for tumor growth inhibition determination. The anti-metastatic function was validated using a transwell migration assay, and using lung metastasis and liver metastasis models. The mechanism of MPT0B390-induced expression was further tested using qPCR and Chromatin IP assay. The anti-angiogenesis function was examined by using transwell migration assay, and Matrigel plug assay. After screening candidate compounds, we identified MPT0B390 as an effective inducer of . We showed that MPT0B390 induces expression significantly and inhibits CRC cell growth and . By inducing TIMP3 expression, MPT0B390 can also exert its anti-metastasis effect to inhibit CRC cell migration and invasion and downregulates migration markers such as , , and . Subsequent Chromatin immunoprecipitation assay revealed that MPT0B390 can significantly inhibit EZH2 expression as well as its binding to promoter region to regulate induction. In addition to the anti-tumor and anti-metastasis capability, MPT0B390 can also induce expression in endothelial cells to inhibit tumor angiogenesis. These data suggest the potential therapeutic applications of the inducer, MPT0B390, for colorectal cancer treatment.

Citing Articles

Identifying cell-type-specific spatially variable genes with ctSVG.

Zhuang H, Shang X, Hou W, Ji Z Res Sq. 2025; .

PMID: 39764138 PMC: 11702777. DOI: 10.21203/rs.3.rs-5655066/v1.

Long-Term Effect of TIMP3 Gene Expression on Thyroid Cancer: A Cure Model Analysis.

Dindarloo M, Fendereski A, Kashi Z, Yazdani-Charati J Asian Pac J Cancer Prev. 2024; 25(10):3627-3634.

PMID: 39471030 PMC: 11711355. DOI: 10.31557/APJCP.2024.25.10.3627.

Tissue Inhibitor of Metalloproteinase 3: Unravelling Its Biological Function and Significance in Oncology.

Lee W, Wu P, Cheng Y, Huang Y Int J Mol Sci. 2024; 25(6).

PMID: 38542164 PMC: 10970424. DOI: 10.3390/ijms25063191.

Identification of RAC1 in promoting brain metastasis of lung adenocarcinoma using single-cell transcriptome sequencing.

Chen M, Li H, Xu X, Bao X, Xue L, Ai X Cell Death Dis. 2023; 14(5):330.

PMID: 37202394 PMC: 10195834. DOI: 10.1038/s41419-023-05823-y.

Impact of Clinicopathological Characteristics and Tissue Inhibitor of Metalloproteinase-3 Polymorphism Rs9619311 on Biochemical Recurrence in Taiwanese Patients with Prostate Cancer.

Hsieh C, Lin C, Wang S, Chou Y, Chien M, Wen Y Int J Environ Res Public Health. 2023; 20(1).

PMID: 36612628 PMC: 9819570. DOI: 10.3390/ijerph20010306.

References

Defamie V, Sanchez O, Murthy A, Khokha R . TIMP3 controls cell fate to confer hepatocellular carcinoma resistance. Oncogene. 2014; 34(31):4098-108. DOI: 10.1038/onc.2014.339. View

Clark I, Swingler T, Sampieri C, Edwards D . The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol. 2008; 40(6-7):1362-78. DOI: 10.1016/j.biocel.2007.12.006. View

Mylona E, Magkou C, Giannopoulou I, Agrogiannis G, Markaki S, Keramopoulos A . Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: relation to tumor phenotype and clinical outcome. Breast Cancer Res. 2006; 8(5):R57. PMC: 1779495. DOI: 10.1186/bcr1607. View

Thaler F, Colombo A, Mai A, Amici R, Bigogno C, Boggio R . Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors. J Med Chem. 2009; 53(2):822-39. DOI: 10.1021/jm901502p. View

Hilska M, Roberts P, Collan Y, Laine V, Kossi J, Hirsimaki P . Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer. 2007; 121(4):714-23. DOI: 10.1002/ijc.22747. View

Baker A, Edwards D, Murphy G . Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci. 2002; 115(Pt 19):3719-27. DOI: 10.1242/jcs.00063. View

Shinojima T, Yu Q, Huang S, Li M, Mizuno R, Liu E . Heterogeneous epigenetic regulation of TIMP3 in prostate cancer. Epigenetics. 2012; 7(11):1279-89. PMC: 3499329. DOI: 10.4161/epi.22333. View

Smith M, Kung H, Durum S, Colburn N, Sun Y . TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells. Cytokine. 1997; 9(10):770-80. DOI: 10.1006/cyto.1997.0233. View

Arpino V, Brock M, Gill S . The role of TIMPs in regulation of extracellular matrix proteolysis. Matrix Biol. 2015; 44-46:247-54. DOI: 10.1016/j.matbio.2015.03.005. View

10.

Murphy G . Tissue inhibitors of metalloproteinases. Genome Biol. 2011; 12(11):233. PMC: 3334591. DOI: 10.1186/gb-2011-12-11-233. View

11.

Somoza J, Skene R, Katz B, Mol C, Ho J, Jennings A . Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure. 2004; 12(7):1325-34. DOI: 10.1016/j.str.2004.04.012. View

12.

Ahonen M, Ala-Aho R, Baker A, George S, Grenman R, Saarialho-Kere U . Antitumor activity and bystander effect of adenovirally delivered tissue inhibitor of metalloproteinases-3. Mol Ther. 2002; 5(6):705-15. DOI: 10.1006/mthe.2002.0606. View

13.

Anania M, Sensi M, Radaelli E, Miranda C, Vizioli M, Pagliardini S . TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells. Oncogene. 2011; 30(27):3011-23. DOI: 10.1038/onc.2011.18. View

14.

Yu W, Yu S, Meng Q, Brew K, Woessner Jr J . TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem. 2000; 275(40):31226-32. DOI: 10.1074/jbc.M000907200. View

15.

Qi J, Anand-Apte B . Tissue inhibitor of metalloproteinase-3 (TIMP3) promotes endothelial apoptosis via a caspase-independent mechanism. Apoptosis. 2015; 20(4):523-34. PMC: 4351133. DOI: 10.1007/s10495-014-1076-y. View

16.

Qi J, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M . A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med. 2003; 9(4):407-15. DOI: 10.1038/nm846. View

17.

Lin H, Zhang Y, Wang H, Xu D, Meng X, Shao Y . Tissue inhibitor of metalloproteinases-3 transfer suppresses malignant behaviors of colorectal cancer cells. Cancer Gene Ther. 2012; 19(12):845-51. DOI: 10.1038/cgt.2012.70. View

18.

Vannini A, Volpari C, Filocamo G, Casavola E, Brunetti M, Renzoni D . Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci U S A. 2004; 101(42):15064-9. PMC: 524051. DOI: 10.1073/pnas.0404603101. View

19.

Ninomiya I, Kawakami K, Fushida S, Fujimura T, Funaki H, Takamura H . Quantitative detection of TIMP-3 promoter hypermethylation and its prognostic significance in esophageal squamous cell carcinoma. Oncol Rep. 2008; 20(6):1489-95. View

20.

Baker A, George S, Zaltsman A, Murphy G, Newby A . Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer. 1999; 79(9-10):1347-55. PMC: 2362728. DOI: 10.1038/sj.bjc.6690217. View